On 12 May 2022, the Supreme Court of Canada dismissed an application by Canada RNA Biochemical (C-RNA) for leave to appeal(1) a decision of the Federal Court of Appeal relating to the refusal of a natural health product (NHP) licence for C-RNA's oral lumbrokinase capsules (Boluoke).

The Federal Court of Appeal did not find any reviewable error (for further details, see "Federal Court of Appeal upholds minister of health's refusal to grant NHP licence for Boluoke") in:

For further information on this topic please contact Malcolm Harvey at Smart & Biggar by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar website can be accessed at www.smartbiggar.ca.


(1) Docket No. 39994.